Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ICMT | O60725 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745791 | 1.00 | CNR1 (0.43) | CNR1NPC1ICMTMAPTP2RX7 | |
| SCHEMBL23745701 | 0.94 | CNR1 (0.43) | CNR1NPC1ICMTMAPTP2RX7 | |
| SCHEMBL23745698 | 0.94 | CNR1 (0.43) | CNR1NPC1ICMTMAPTP2RX7 | |
| SCHEMBL23745829 | 0.91 | ICMT (0.41) | CNR1NPC1ICMTMAPTBCHE | |
| SCHEMBL23745594 | 0.90 | CNR1 (0.42) | CNR1ICMTMAPTMEN1KMT2A | |
| SCHEMBL23745532 | 0.90 | CNR1 (0.42) | CNR1ICMTMAPTMEN1KMT2A | |
| SCHEMBL23745577 | 0.90 | CNR1 (0.42) | CNR1ICMTMAPTMEN1KMT2A | |
| SCHEMBL23745575 | 0.90 | CNR1 (0.42) | CNR1ICMTMAPTMEN1KMT2A | |
| SCHEMBL23721885 | 0.90 | CNR1 (0.42) | CNR1ICMTMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL23722010 | 0.89 | CNR1 (0.41) | CNR1ICMTMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | CNR1 1651/4885NPC1 564/4885ICMT 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.